Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial-Reference-Cited by-同舟云学术

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Published:2024-09-14 Issue: Volume: Page:
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Shatsky Rebecca A.,Trivedi Meghna S.,Yau Christina,Nanda Rita^ORCID,Rugo Hope S.^ORCID,Davidian Marie,Tsiatis Butch,Wallace Anne M.,Chien A. Jo,Stringer-Reasor Erica,Boughey Judy C.^ORCID,Omene Coral,Rozenblit Mariya,Kalinsky Kevin^ORCID,Elias Anthony D.,Vaklavas Christos^ORCID,Beckwith Heather,Williams Nicole,Arora Mili,Nangia Chaitali,Roussos Torres Evanthia T.^ORCID,Thomas Brittani,Albain Kathy S.,Clark Amy S.,Falkson Carla,Hershman Dawn L.,Isaacs Claudine^ORCID,Thomas Alexandra^ORCID,Tseng Jennifer,Sanford Amy,Yeung Kay,Boles Sarah,Chen Yunni Yi,Huppert Laura,Jahan Nusrat,Parker Catherine,Giridhar Karthik,Howard Frederick M.,Blackwood M. Michele,Sanft Tara,Li Wen,Onishi Natsuko^ORCID,Asare Adam L.,Beineke Philip,Norwood Peter,Brown-Swigart Lamorna^ORCID,Hirst Gillian L.^ORCID,Matthews Jeffrey B.,Moore Brian,Symmans W. Fraser^ORCID,Price Elissa,Heditsian Diane,LeStage Barbara,Perlmutter Jane,Pohlmann Paula^ORCID,DeMichele Angela^ORCID,Yee Douglas^ORCID,van ’t Veer Laura J.^ORCID,Hylton Nola M.,Esserman Laura J.^ORCID

Funder

U.S. Department of Health & Human Services | National Institutes of Health

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41591-024-03267-1.pdf

Reference40 articles.

1. Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12–49 (2024).

2. Giaquinto, A. N. et al. Breast cancer Statistics, 2022. CA Cancer J. Clin. 72, 524–541 (2022).

3. Swain, S. M., Whaley, F. S. & Ewer, M. S. Congestive heart failure in patients treated with doxorubicin. Cancer 97, 2869–2879 (2003).

4. Harrington, D. & Parmigiani, G. I-SPY 2—a glimpse of the future of phase 2 drug development? N. Engl. J. Med. 375, 7–9 (2016).

5. Das, S. & Lo, A. W. Re-inventing drug development: a case study of the I-SPY 2 breast cancer clinical trials program. Contemp. Clin. Trials 62, 168–174 (2017).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial;Nature Medicine;2024-09-14